This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
26 Jul 2012

Novavax Influenza Vaccine Meets Primary Endpoints in Phase Two Trial

The company said the quadrivalent seasonal influenza virus-like particle vaccine triggered an immune response against all four strains of the bug after 21 days.

US-based pharma company Novavax has announced that its experimental influenza vaccine has met its primary objectives of demonstrating safety and immune response in a phase two clinical trial.

 

The company said the quadrivalent seasonal influenza virus-like particle (VLP) vaccine, tested on 500 people in Australia, triggered an immune response against all four strains of the bug after 21 days. The vaccine was also well-tolerated with no serious adverse events observed.

 

Novavax also noted that the vaccine has the potential to fulfill the US Food and Drug Administration (FDA) Center for Biologics Evaluation and Research criteria for accelerated approval.

 

The

Related News